HM Pharma
Turnover is estimated at about €900,000, probably between €590,000 and €1.9m. The abbreviated or micro format does not state turnover.
Balance sheet
balance sheet total €1.3m on 31-03-2026in euro
in euro
Position in the sector
28.3%
Higher than 40% of the 13,315 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
2.09
Higher than 65% of the 13,174 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
5.4%
Higher than 55% of the 13,235 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
Staff
€41,592
Staff costs divided by the average number of full-time equivalents.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| 109,093 | 120,312 | 110,204 | 103,929 | 93,946 | ||
| 86,512 | 91,765 | 89,701 | 83,482 | 78,322 | ||
| 772,078 | 0 | 3,517 | 49,507 | 106,849 | ||
| 42,937 | 34,672 | 84,107 | -69,093 | - | ||
| 208,316 | 235,156 | 154,259 | 77,196 | 157,449 | ||
| 28.3% | 65.5% | 51.9% | 43.1% | 19.8% | ||
| 2.09 | 3.35 | 2.14 | 1.67 | 2.60 | ||
| 1.41 | 2.11 | 1.32 | 0.76 | 1.51 | ||
| 2.54 | 0.53 | 0.93 | 1.32 | 4.06 | ||
| 19.2% | 25.7% | 33.8% | 50.4% | 98.6% | ||
| 5.4% | 16.8% | 17.5% | 21.7% | 19.5% | ||
| 34.04 | 27.02 | 22.58 | 31.46 | 22.45 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
1.3m | 437,528 | 409,860 | 327,404 | 353,326 | |
21/28 |
855,722 | 102,176 | 120,253 | 134,559 | 97,398 | |
22/27 |
98,962 | 100,553 | 118,629 | 132,936 | 97,398 | |
22 |
63,536 | 67,163 | 78,069 | 88,976 | 96,697 | |
23 |
2,608 | 2,504 | 3,472 | 1,555 | - | |
24 |
32,818 | 30,886 | 37,087 | 42,405 | 701 | |
28 |
756,760 | 1,624 | 1,624 | 1,624 | - | |
29/58 |
398,750 | 335,351 | 289,607 | 192,845 | 255,928 | |
3 |
129,479 | 123,732 | 110,437 | 104,460 | 107,336 | |
30/36 |
129,479 | 123,732 | 110,437 | 104,460 | 107,336 | |
40/41 |
17,690 | 13,875 | 10,596 | 10,912 | 12,518 | |
40 |
3,360 | 6,787 | 7,384 | 6,587 | 12,518 | |
41 |
14,330 | 7,088 | 3,212 | 4,325 | - | |
54/58 |
181,683 | 138,746 | 104,073 | 19,967 | 89,059 | |
490/1 |
69,899 | 58,998 | 64,501 | 57,507 | 47,015 | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
1.3m | 437,528 | 409,860 | 327,404 | 353,326 | |
10/15 |
354,554 | 286,574 | 212,885 | 141,008 | 69,871 | |
10/11 |
1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |
13 |
353,554 | 285,574 | 211,885 | 140,008 | 68,871 | |
133 |
353,554 | 285,574 | 211,885 | 140,008 | 68,871 | |
17/49 |
899,919 | 150,953 | 196,975 | 186,397 | 283,455 | |
17 |
704,065 | 39,919 | 59,352 | 66,974 | 182,875 | |
170/4 |
704,065 | 39,919 | 59,352 | 66,974 | 182,875 | |
42/48 |
190,434 | 100,195 | 135,348 | 115,649 | 98,479 | |
42 |
70,854 | 7,433 | 7,622 | 10,611 | 10,490 | |
44 |
101,495 | 66,907 | 91,813 | 71,537 | 57,923 | |
440/4 |
101,495 | 66,907 | 91,813 | 71,537 | 57,923 | |
45 |
18,085 | 25,855 | 35,913 | 33,501 | 29,006 | |
450/3 |
1,720 | 10,818 | 21,347 | 19,849 | 14,628 | |
454/9 |
16,365 | 15,037 | 14,566 | 13,652 | 14,378 | |
47/48 |
- | - | - | - | 1,061 | |
492/3 |
5,420 | 10,839 | 2,274 | 3,774 | 2,100 | |
| Income statement | ||||||
9900 |
192,466 | 196,403 | 184,268 | 171,578 | 165,801 | |
62 |
83,185 | 75,905 | 73,890 | 67,487 | 71,801 | |
630 |
18,532 | 18,076 | 17,824 | 12,346 | 9,451 | |
640/8 |
188 | 186 | 175 | 162 | 55 | |
9901 |
90,561 | 102,236 | 92,380 | 91,583 | 84,495 | |
75/76B |
5,013 | 2,843 | 4,208 | 1,919 | 994 | |
75 |
5,013 | 2,843 | 4,208 | 1,919 | 994 | |
65/66B |
3,205 | 4,452 | 4,882 | 3,303 | 4,184 | |
65 |
3,205 | 4,452 | 4,882 | 3,303 | 4,184 | |
9903 |
92,368 | 100,627 | 91,706 | 90,199 | 81,304 | |
67/77 |
24,389 | 26,938 | 19,829 | 19,063 | 12,433 | |
9904 |
67,980 | 73,689 | 71,878 | 71,136 | 68,871 | |
9905 |
67,980 | 73,689 | 71,878 | 71,136 | 68,871 | |
| Appropriation of the result | ||||||
9906 |
67,980 | 73,689 | 71,878 | 71,136 | 68,871 | |
691/2 |
67,980 | 73,689 | 71,878 | 71,136 | 68,871 | |
6921 |
67,980 | 73,689 | 71,878 | 71,136 | 68,871 | |
| Social balance sheet | ||||||
9087 |
2 | 2 | 2 | 2.5 | 2 | |
Hours worked1013 |
1,972 | 2,031 | 1,983 | 1,658 | 1,878 | |
| Document | ||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2026 at the NBB, filed on 28-09-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-03-2026 | abbreviated format | 28-09-2026 | 2026-00532152 | |
| 31-03-2025 | abbreviated format | 14-10-2025 | 2025-00543394 | |
| 31-03-2024 | abbreviated format | 15-10-2024 | 2024-00508333 | |
| 31-03-2023 | abbreviated format | 09-10-2023 | 2023-00480810 | |
| 31-03-2022 | micro format | 10-10-2022 | 2022-20458272 |
Subsidies and aid
Flemish government 2023, 1 entry, €159 awarded, €159 paid
Social balance sheet
| Item | 31-03-2026 | 31-03-2025 | 31-03-2024 | 31-03-2023 | 31-03-2022 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 2 | 2 | 2 | 2 | 2 |
| part-time | 2 | 2 | 2 | 2 | 2 |
| in full-time equivalents | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 |
| 1.1 | 1.1 | 1.1 | 1.2 | 1.1 | |
| On a permanent contract | 2 | 2 | 2 | 2 | 2 |
| Joined | - | - | - | 1 | 2 |
| Left | - | - | - | 1 | 0 |
Source: social balance sheet in the 2022 to 2026 annual accounts
Investments
fixed assets acquired| Item | 31-03-2026 | 31-03-2025 | 31-03-2024 | 31-03-2023 | 31-03-2022 |
|---|---|---|---|---|---|
| Tangible fixed assets | €16,942 | - | €3,517 | €47,884 | €106,849 |
| Financial fixed assets | €755,136 | - | - | €1,624 | - |
| €18,532 | €18,076 | €17,824 | €12,346 | €9,451 |
Source: notes to the 2022 to 2026 annual accounts (statement of fixed assets)
Insights on HM Pharma
The operating result for 2026 is 11% lower than in 2025 and the lowest since 2022.
Debt's share of the balance-sheet total rises from 34.5% to 71.7%. Equity and debt are higher.